Health
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name TYZAVAN™ (vancomycin injection, USP).1 TYZAVAN™ is offered in pre-filled ready-to-use bags that will help hospitals, pharmacists, doctors, and nurses treat patients faster, more easily, and with reduced risk. This is another example of how Hikma is using its capabilities as a leading g
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"Ready-to-use sepsis therapy marks new advancement in time-critical treatment","length":76,"tagName":"p"},{"type":"text","content":"LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name TYZAVAN™ (vancomycin injection, USP).1 TYZAVAN™ is offered in pre-filled ready-to-use bags that will help hospitals, pharmacists, doctors, and nurses treat patients faster, more easily, and with reduced risk. This is another example of how Hikma is using its capabilities as a leading generic pharmaceutical company to serve the growing needs of U.S. medical professionals and their patients.","length":648,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hikma Pharmaceuticals USA Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hikma Pharmaceuticals USA Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":108,"url":"https://media.zenfs.com/en/prnewswire.com/fcdee251665d184651b9926f5e9abe51"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/brP0E8SqJTDAbtPocMJv2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fcdee251665d184651b9926f5e9abe51","width":400,"height":108}},"href":"https://mma.prnewswire.com/media/1165956/Hikma_Primary_Coral_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"TYZAVAN™ is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved: (i) septicemia; (ii) infective endocarditis; (iii) skin and skin structure infections; (iv) bone infections; and (v) lower respiratory tract infections.","length":373,"tagName":"p"},{"type":"text","content":"The name TYZAVAN™ stands for "time-saving vancomycin," reflecting its ready-to-use dosage form and its purpose: delivering timely, simplified treatment when every minute counts. TYZAVAN™ is the only FDA-approved vancomycin injection available for adults and pediatric patients (1 month and older) that can be stored at room temperature and used immediately eliminating the need for compounding, thawing, assembly or...